FDC Limited announces Q4 FY26 results

FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) has announced its financial results for the fourth quarter and year ended March 31, 2026.

Q4 FY26 revenue from operations stood at Rs. 585 crores, registering a robust growth of 18.9% Y-o-Y. All the three business segments achieved healthy growth with Domestic Formulations business growing by 8.5%, Export Formulations business growing by 99.3% and API business growing by 38.6%. For FY26, revenue from operations stood at Rs. 2,171 crores with a growth of 3.0%.

The US business overcoming the earlier challenges delivered strong performance in Q4 FY26. Revenue from supplies stood at Rs. 71 crores reflecting a Y-o-Y growth of 165.1%, driven by improved execution and demand momentum. Overall US business revenue grew 46.9% Y-o-Y, with improved profit share from the US partners.

EBITDA for Q4 FY26 stood at Rs. 106 crores, with margins at 18.2% compared to 11.0% last year on the back of enhanced operational efficiencies. FY26 EBITDA margin improved from 15.4% to 15.9% Y-o-Y driven by higher gross margin.

Domestic Formulations:

Domestic Formulations business bounced back in Q4 FY26 with a revenue of Rs. 452 crores registering a healthy growth of 8.5% Y-o-Y. For FY26, Domestic Formulations sales were Rs. 1,781 crores, displaying a muted growth of 0.1% compared to the corresponding period last year, due to subdued performance in top brands like Zifi, Electral and Enerzal. Domestic Formulations business contributed 78% to total consolidated sales during the quarter and 82% for FY26.

According to the secondary sales data by IQVIA (MAT March 31, 2026), the Company recorded a 1.7% growth.

Export Formulations:

Export Formulations sales stood at Rs. 89 crores in Q4 FY26, registering a growth of 99.3% Y-o-Y, contributing 15% to company's consolidated sales. For FY26, Export Formulations sales were Rs. 260 crores, reflecting a 23.5% growth compared to the same period last year. Export Formulations performance has improved consistently over the last 2-3 quarters, supported by improved supplies and better execution across US and focused markets.

During the quarter, the Company received U.S. FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg and 200mg.

APIs:

API business registered sales of Rs. 42 crores in Q4 FY26, up by 38.6% Y-o-Y and accounting for 7% of total consolidated sales. During FY26, the API business grew by 8.5% registering sales of Rs. 121 crores.

Shares of FDC Limited was last trading in BSE at Rs. 427.55 as compared to the previous close of Rs. 403.70. The total number of shares traded during the day was 89316 in over 2361 trades.

The stock hit an intraday high of Rs. 439.00 and intraday low of 408.50. The net turnover during the day was Rs. 37781018.00.

Source : Equity Bulls

Keywords

FDC INE258B01022 Pharmaceuticals Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate